Ocular cicatricial pemphigoid
disease diseaseOn this page
Also known as cicatricial pemphigoid, ocularOCPocular pemphigoidpemphigoid, ocular cicatricial
Summary
Ocular cicatricial pemphigoid (MONDO:0008109) is a disease and 7 clinical trials. Top therapeutic interventions include riboflavin and rituximab. A subtype of mucous membrane pemphigoid — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 7
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ocular cicatricial pemphigoid |
| Mondo ID | MONDO:0008109 |
| EFO | EFO:0008610 |
| OMIM | 164185 |
| Orphanet | 99922 |
| ICD-11 | 953963439 |
| NCIT | C84939 |
| SNOMED CT | 314757003, 34250006 |
| UMLS | C1282359 |
| MedGen | 266181 |
| GARD | 0008759 |
| MedDRA | 10067776 |
| Is cancer (heuristic) | no |
Also known as: cicatricial pemphigoid, ocular · OCP · ocular cicatricial pemphigoid · ocular pemphigoid · pemphigoid, ocular cicatricial
Disease family
This is a subtype of mucous membrane pemphigoid. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › autoimmune bullous skin disease › mucous membrane pemphigoid › ocular cicatricial pemphigoid
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 7.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00584935 | PHASE1/PHASE2 | COMPLETED | Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid |
| NCT01582880 | PHASE1/PHASE2 | COMPLETED | Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis |
| NCT06926478 | PHASE1 | NOT_YET_RECRUITING | Subconjunctival Humira for Boston Keratoprosthesis |
| NCT02149732 | Not specified | AVAILABLE | Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation |
| NCT03421548 | Not specified | WITHDRAWN | Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1 |
| NCT05347667 | Not specified | COMPLETED | Menstrual Cycle Phase and Oral Contraceptive Pill (OCP) Use on Muscle Protein Synthesis |
| NCT06412718 | Not specified | UNKNOWN | Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| RIBOFLAVIN | 4 | 1 |
| RITUXIMAB | 4 | 1 |
| CHEMBL511565 | 0 | 1 |
| CHEMBL5267279 | 0 | 1 |
Related Atlas pages
- Drugs: Riboflavin, Rituximab